Immune dysfunction due to fatty liver disease may increase susceptibility to infections.

Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.

Offering hepatitis C treatment at the point of diagnosis streamlines care, saving both time and money.

Study findings suggest this circuitry might be targeted in potential therapies for a variety of substance use disorders.

Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.

The protein-based vaccine works in a different way than the mRNA vaccines from Moderna and Pfizer-BioNTech.

However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.

The technology, developed by Katalin Karikó and Drew Weissman, also holds promise for HIV vaccines and cancer treatment.

Hepatitis C prevalence was higher among people with unstable housing and those who injected drugs every day.

NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.